Can Chemotherapy Dosing Be Individualized?

Patricia Weiss

chemotherapy
CJON 2008, 12(6), 975-977. DOI: 10.1188/08.CJON.975-977

Jump to a section

    References

    Abramowitz, P. (2006). The financial impact of genomics. Retrieved February 11, 2006, from http://hcfinance.com/dectech2.htm
    Alcalde, M. G., & Rothstein, M. A. (2002). Pharmacogenomics: Ethical concerns for research and pharmacy practice. American Journal of Health-System Pharmacy, 59(22), 2239-2240.
    Genomic Health, Inc. (2008). Oncotype DX breast cancer assay. Retrieved November 11, 2008, from http://www.genomichealth.com/oncotype
    Guttmacher, A. E., & Collins, F. S. (2002). Genomic medicine—A primer. New England Journal of Medicine, 347(19), 1512-1520.
    Ingelman-Sundberg, M., & Rodriguez-Antona, C. (2005). Pharmacogenetics of drugmetabolizing enzymes: Implications for a safer and more effective drug therapy. Philosophical Transactions of the Royal Society of London. Series B, 360(1460), 1563-1570.
    Lee, S. S. (2005). Racializing drug design: Implications of pharmacogenomics for health disparities. American Journal of Public Health, 95(12), 2133-2138.
    Ma, M., Woo, M. K., & McLeod, H. L. (2002). Genetic basis of drug metabolism. American Journal of Health-System Pharmacy, 59(21), 2061-2069.
    Meadows, M. (2005). Genomics and personalized medicine. FDA Consumer, 39(6), 12-17.
    O'Malley, P. (2005). Ethnic pharmacology: Science, research, race, and market share. Clinical Nurse Specialist, 19(6), 291-293.
    Rotea, W., Jr., & Saad, E. D. (2003). Targeted drugs in oncology: New names, new mechanisms, new paradigm. American Journal of Health-System Pharmacy, 60(12), 1233-1245.
    Stearns, V., Johnson, M., Rae, J., Morocho, A., Novielli, A., Bhargava, P., et al. (2003). Active tamoxifen metabolite plasma concentrations after co-administration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. Journal of the National Cancer Institute, 95(23), 1758-1764.
    Tejpar, S., Peeters, M., Humblet, Y., Vermorken, J. B., De Hertogh, G., De Roock, W., et al. (2008). Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecanrefractory metastatic colorectal cancer, treated with irinotecan and escalating doses of cetuximab: The EVEREST experience [Abstract 4001]. Journal of Clinical Oncology, 26(15, Suppl.), 2008. Retrieved August 13, 2008, from http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmvie… http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=34722
    Wood, L., & Muehlbauer, P. (2003). Molecular and targeted therapies in cancer care: From concept to chairside [Monograph]. Retrieved October 30, 2008, from http://oesweb.com/pdf/monographs/Genentech2468.pdf